Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Black Diamond Therapeutics (BDTX) Equity Average (2019 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Equity Average for 3 consecutive years, with $235.0 million as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Equity Average fell 29.9% year-over-year to $235.0 million, compared with a TTM value of $235.0 million through Sep 2021, down 29.9%, and an annual FY2020 reading of $130.3 million, changed N/A over the prior year.
  • Equity Average was $235.0 million for Q3 2021 at Black Diamond Therapeutics, down from $265.9 million in the prior quarter.
  • Across five years, Equity Average topped out at $349.2 million in Q2 2020 and bottomed at -$43.5 million in Q4 2019.
  • Average Equity Average over 3 years is $184.7 million, with a median of $250.4 million recorded in 2021.
  • The sharpest move saw Equity Average skyrocketed 1478.77% in 2020, then decreased 29.9% in 2021.
  • Year by year, Equity Average stood at -$43.5 million in 2019, then soared by 830.43% to $317.6 million in 2020, then decreased by 26.0% to $235.0 million in 2021.
  • Business Quant data shows Equity Average for BDTX at $235.0 million in Q3 2021, $265.9 million in Q2 2021, and $294.3 million in Q1 2021.